PS
RXRX icon

Principal Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

Principal Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,240
Closed -$6.05K – 3103
2025
Q3 		$6.05K Hold
1,240
– – ﹤0.01% 2904
2025
Q2 		$6.27K Sell
1,240
-78
-6% -$383 ﹤0.01% 2798
2025
Q1 		$8.91K Hold
1,318
– – ﹤0.01% 2571
2024
Q4 		$8.91K Buy
1,318
+17
+1% +$114 ﹤0.01% 2566
2024
Q3 		$8.57K Buy
1,301
+48
+4% +$344 ﹤0.01% 2504
2024
Q2 		$9.4K Sell
1,253
-165
-12% -$1.44K ﹤0.01% 2421
2024
Q1 		$14.1K Buy
1,418
+1,043
+278% +$11.6K ﹤0.01% 2179
2023
Q4 		$3.7K Buy
+375
New +$2.67K ﹤0.01% 2641

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Principal Securities's RXRX Position: Q4 2025 in Review

Principal Securities sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 1,240 shares — an estimated $6.05K sold.

Principal Securities first reported a position in RXRX in Q4 2023 and held it in 8 quarters. The position peaked at $14.1K in Q1 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Principal Securities reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 1,240 Recursion Pharmaceuticals shares in Q4 2025, an estimated $6.05K.
  • Principal Securities first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Recursion Pharmaceuticals position peaked at $14.1K in Q1 2024.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.